Phospholipids particles inhalation in therapy of asthma: randomized placebo-controlled trial

Alexander V. Lisitsa; Alexander V. Averyanov; Svetlana K. Sodaeva; Igor A. Klimanov; Sergey E. Mikhailov

doi:10.17816/clinpract83813

Journal of Clinical Practice ›› 2012, Vol. 3 ›› Issue (1) : 15 -22. DOI: 10.17816/clinpract83813

Original Study Articles

research-article

Phospholipids particles inhalation in therapy of asthma: randomized placebo-controlled trial

Author information +

History +

PDF

Abstract

The prospective single-blind randomized placebo-controlled study was performed.

The aim of the study was to investigate the effectiveness and safety of phospholipids' particles inhalation in patients with bronchial asthma. The results obtained demonstrate the statistically significant improvements both in clinical status and lung function tests. No any clinically significant adverse events were registered.

Keywords

asthma / phospholipids inhalation / randomized controlled study

Cite this article

Download citation ▾

Alexander V. Lisitsa, Alexander V. Averyanov, Svetlana K. Sodaeva, Igor A. Klimanov, Sergey E. Mikhailov. Phospholipids particles inhalation in therapy of asthma: randomized placebo-controlled trial. Journal of Clinical Practice, 2012, 3(1): 15-22 DOI:10.17816/clinpract83813

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Global Initiative for Asthma, National Institute of Health, National Heart Lung and Blood Institute, NHLBI/WHO Workshop report. Global strategy for asthma management and prevention. NHLBI/WHO workshop report 02-3659. January 1995, revised 2010.

[2]	Fireman P., Prenner B., Vincken W. et al. Longterm safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol Ann Allergy Asthma Immunol 2001; 86(5): 557-65.

[3]	Suissa S., Ernst R., Benayoun S. et al. Low-dose inhaled corticosteroids and the prevention of death from asthma N Engl J Med 2000; 343(5); 332-336.

[4]	Pauwels R.A., Löfdahl C.G., Postma D.S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997; 337(20): 1405-1411.

[5]	Fardon T.C., Burns P., Barnes M.L., Lipworth B.J. et al. A comparison of 2 extrafine hydrofluoroalkane- 134a-beclomethasone formulations on methacholine hyperresponsiveness. Ann Allergy Asthma Immunol. 2006; 96(3): 422-430.

[6]	Lazarus S.C., Boushey H.A., Fahy J.V. et al. Longacting ß2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. Jama. 2001; 285 (20): 2583-2593.

[7]	Bateman E.D., Bousquet J., Busse W.W. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004; 170(8): 836-844.

[8]	Godard P., Greillier P., Pigearias B. et al. Mantaining asthma control in persistent asthma: Comparison of three strategies in a 6-month doubleblind randomised study. Respiratory Medicine. 2008; 102: 1124-1131.

[9]	Tampo Y. Studies on membrane factors in iron supported lipid peroxidation. Yakugaki Zasshi. 2000; 120: 387-396.

[10]	Bergamini C.M., Hunte C. Lipids in membrane protein structures. Biochem Biophys Acta. 2004; 1666: 2-18.

[11]	Ипатова O.M. Фосфоглив: механизм действия и применение в клинике. М„ 2005.

[12]	Владимиров Ю.А., Арчаков А.И. Перекисное окисление .липидов в биологических мембранах. М.: Наука, 1972. 252с.

[13]	Лисица А.В., Соодаева С.К., Климанов И.А., Чучалин А.Г. Динамика показателей окислительного стресса у больных, переносящих обострение бронхиальной астмы, на фоне ингаляционной терапии липосомальными препаратами. Пульмонология. 2010; 1: 74-80.